Loading…
← CockpitCompetitor Analysis › PGHH.NS Procter & Gamble Hygiene & Health Care Ltd.Open in the cockpit ↗

Procter & Gamble Hygiene & Health Care Ltd.PGHH.NSCompetitor analysis, valuation and peers

India · INR·FMCG›Household/Personal Care

Indian listed arm of P&G selling feminine hygiene (Whisper) and healthcare products (Vicks) in India.

Momentum laggard 9
Mkt cap
$2.37B
US dollars, full cap
Free float
29%
of shares outstanding
$/day
$1.12M
20-day average traded
Fwd P/E
27.0×
forward earnings
ROIC−WACC
n/a
WACC 12.4%
Hurdle
+14 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · INR₹6,829
1D-2.3%
1W-5.2%
1M-4.5%
3M-17.9%
6M-29.6%
YTD-47.4%
1Y-46.9%
ATR %2.7%
Beta0.38
52w lowhigh48.1% off high

What Procter & Gamble Hygiene & Health Care does

Indian listed arm of P&G selling feminine hygiene (Whisper) and healthcare products (Vicks) in India.

Sells branded goods through distributors and pharmacies. Feminine hygiene is a year-round staple, while Vicks remedies peak in the winter and monsoon months. The brands and know-how come from the US group Procter & Gamble, which controls the company.

Products and services

  • Whisper (feminine hygiene)
  • Vicks (cough/cold remedies)

Customers

  • Retail consumers via general/modern trade
  • Pharmacies

Where it sits in the supply chain

  • Consumer staples
  • Personal care & healthcare FMCG
  • Feminine hygiene & OTC healthcare

What could go right

  • Rising hygiene-product penetration in India
  • Winter cough/cold seasonality upside

What could go wrong

  • Competition from local/Unilever brands
  • Raw material cost inflation

Moat: narrow (brand, distribution). Leading, trusted brands (Whisper, Vicks) with deep retail and pharmacy distribution across India.

Headquarters: Mumbai, India · Founded: 1964 · Employees: 712

Named competitors

Procter & Gamble Hygiene & Health Care at a glance

Size Procter & Gamble Hygiene & Health Care (PGHH.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $2.37B, the 342nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹6,829 on 18 Nov 2026.

Performance Over six months the shares fell 29.6%, against +0.3% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 2.0% over the last twelve months (peer median +3.3%); the operating margin is 23.8% (peer median 10.6%).

Valuation It trades at 27.0× forward earnings against a peer median of 21.5× (8th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 103PGHH.NS 71
Six months, rebased to 100: Procter & Gamble Hygiene & Health Care against the median of its 20 peers (local-currency closes).

Procter & Gamble Hygiene & Health Care financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹42.4B₹42.9B₹45.0B₹39.2B₹39.0B
Revenue growth—-5%+15%0%—
Gross profit₹23.4B₹22.3B₹23.2B₹17.3B₹17.2B
EBITDA₹10.5B₹12.0B₹11.9B₹8.74B₹8.39B
Net income₹7.77B₹8.56B₹8.49B₹6.78B₹5.76B
Free cash flown/a₹9.13B₹5.67B₹8.11B₹5.44B
Capital expendituren/a₹495M₹550M₹444M₹498M
Total debt₹3.30M₹8.70M₹23.2M₹40.3M₹51.0M

Quarterly statements and history in the cockpit →

Procter & Gamble Hygiene & Health Care competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-10%0%+10%2367192820300888GILLETTE2698492269931618904927051900603605EMAMILTDENR79564967300957603983ITP600315PGHH.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Procter & Gamble Hygiene & Health Care is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×2367192820300888GILLETTE2698492269931618904927051900603605EMAMILTDENR795649671044300957603983ITP600315PGHH.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Procter & Gamble Hygiene & Health Care is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%2367300888GILLETTE26981618904927051900603605EMAMILTD49671044300957ITP600315PGHH.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Procter & Gamble Hygiene & Health Care is the large dot.

Procter & Gamble Hygiene & Health Care competitors and peer comparison

Head to head with its named competitors (PGHH.NS vs HINDUNILVR.NS vs EMAMILTD.NS vs DABUR.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Procter & Gamble Hygiene & Health Care PGHH.NS$2.37B-30%-2%24%27.0×21.2%
Hindustan Unilever HINDUNILVR.NS$50.0B-11%+6%21%41.4×27.4%
Emami EMAMILTD.NS$1.94B-5%+13%20%23.4×21.5%
Dabur India DABUR.NS$7.16B-16%+9%15%31.8×27.4%
Reckitt Benckiser RKT.L$47.5B+22%-2%28%16.7×2.1%
Kenvue KVUEn/a+12%n/an/an/an/a

How Procter & Gamble Hygiene & Health Care compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Procter & Gamble Hygiene & Health Care against its 20 peers (data as of 18 Nov 2026)
MeasurePGHH.NSPeer medianRank in peer set
1-month return-4.5%+2.2%8th lowest of 21
6-month return-29.6%+0.3%3rd lowest of 21
Distance from 52-week high-48.1%-24.0%2nd lowest of 21
Revenue growth (TTM)-2.0%+3.3%6th lowest of 21
Operating margin23.8%10.6%4th highest of 21
Forward P/E27.0×21.5×8th most expensive of 21
Growth the price implies (Req g, 7 yrs)21.2%-1.8%2nd most demanding of 17
Growth delivered (Del g)+7.4%+3.8%8th highest of 17
Hurdle (Req g minus delivered)+13.8 pp-4.1 pp4th most demanding of 17
EV / EBITDA20.4×11.3×3rd most expensive of 15
Net debt / EBITDA-0.7×-1.5×8th most indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Procter & Gamble Hygiene & Health Care PGHH.NSIndia$2.37B-30%-2%24%27.0×21.2%+7.4%
Giant Biogene 2367.HKHong Kong$2.47B-32%-10%32%8.6×-10.7%+34.9%
Cosmax 192820.KSSouth Korea$2.51B+53%+25%8%18.8×n/an/a
Winner Medical 300888.SZChina$2.53B-6%+4%11%19.9×-5.2%-2.6%
Gillette India GILLETTE.NSIndia$2.53B-5%+8%28%37.1×14.9%+13.0%
Softcare 2698.HKHong Kong$2.20B+5%+25%25%14.4×9.1%+20.9%
KOSE 4922.TJapan$2.16B+16%+4%5%29.9×n/an/a
Blue Moon 6993.HKHong Kong$2.07B-4%-2%-2%103.3×n/an/a
Kolmar Korea 161890.KSSouth Korea$2.05B+14%+16%10%14.3×-1.6%+15.5%
Pola Orbis 4927.TJapan$2.04B+15%+1%11%30.6×-2.0%-0.7%
LG H&h 051900.KSSouth Korea$2.81B-14%-3%3%23.1×-4.6%-4.1%
Proya Cosmetics 603605.SSChina$2.87B-13%+2%13%10.9×-5.3%+23.1%
Emami EMAMILTD.NSIndia$1.94B-5%+13%20%23.4×21.5%+5.6%
Energizer ENRUnited States$1.94B+71%0%17%9.1×-5.1%-0.5%
Pigeon 7956.TJapan$1.76B+26%+8%13%27.9×-2.4%+1.9%
Kobayashi Pharmaceutical 4967.TJapan$3.25B+20%+2%6%48.7×18.0%+1.9%
Hengan Int'l 1044.HKHong Kong$3.27B-12%+2%11%9.1×-8.2%-0.1%
Yunnan Botanee Bio-Technology 300957.SZChina$1.69B-33%+7%9%19.1×2.6%+15.3%
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a
Interparfums ITP.PAFrance$3.49B+66%-4%18%26.9×15.6%+19.6%
Shanghai Jahwa United 600315.SSChina$1.61B-15%+9%2%15.4×15.3%-2.1%

Questions

Who are Procter & Gamble Hygiene & Health Care's main competitors?
Named competitors: Hindustan Unilever (HINDUNILVR.NS), Emami (EMAMILTD.NS), Dabur India (DABUR.NS), Reckitt (RKT.L), Kenvue (KVUE). The cockpit's measured peer set (industry) also includes Giant Biogene (2367.HK), Cosmax (192820.KS), Winner Medical (300888.SZ), Gillette India (GILLETTE.NS), Softcare (2698.HK), KOSE (4922.T).
Is Procter & Gamble Hygiene & Health Care expensive compared with its peers?
On forward p/e it trades at 27.0× against a peer median of 21.5×, 8th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Procter & Gamble Hygiene & Health Care stock performed?
Over six months to 18 Nov 2026 the shares returned -29.6% against +0.3% for the median peer; over one year -46.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.